The blood test was found to detect colorectal cancer with 92 percent sensitivity and 97 percent specificity. It also was shown to have 89 percent sensitivity and 97 percent specificity detecting early-stage cancer. The test uses single target sequence analyses of multiomics markers, computational biology and machine learning.
“We have built a test that can ‘read’ cancer’s tissue-specific signal in blood on a fragment level,” Universal Diagnostics’ managing director, Christian Hense, said. “We know that if we can detect cancer early, or identify pre-cancer stage patients before they develop cancer, the survival rates increase exponentially.”
Universal Diagnostics focuses on identifying early-stage cancer and is developing its Signal-X platform to detect multiple cancer types. Its Signal-C platform focuses on colorectal cancer and adenomatous polyps.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
